Search

Your search keyword '"Nielsen, D.L."' showing total 49 results
Start Over Author "Nielsen, D.L."
49 results on '"Nielsen, D.L."'

29. Circulating Free Dna and Plasma Kras Mutations in Metastatic Colorectal Cancer Patients Treated with Bi-Weekly Cetuximab and Irinotecan

Author

Spindler, K.G., primary, Pallisgaard, N., additional, Skovgaard, K., additional, Andersen, R., additional, Hendel, H., additional, Yilmaz, M., additional, Pfeiffer, P., additional, Nielsen, D.L., additional, Johansen, J., additional, Hoegdall, E., additional, Jakobsen, A., additional, and Vittrup, B., additional

Published
2014
Full Text
View/download PDF

34. Antiangiogenic therapy for breast cancer

Author

Nielsen, D.L., Andersson, M., Andersen, Jon Alexander Lykkegaard, Kamby, C., Nielsen, D.L., Andersson, M., Andersen, Jon Alexander Lykkegaard, and Kamby, C.

Abstract

Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. Currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Small molecular inhibitors of VEGF tyrosine kinase activity, such as sorafenib, appear promising. While, the role of sunitinib and inhibitors of mammalian target of rapamycin (mTOR) in breast cancer has to be defined. Several unanswered questions remain, such as choice of drug(s), optimal duration of therapy and patient selection criteria

Published
2010

35. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer

Author

Roslind, A., Knoop, A.S., Jensen, Maiken Brit, Johansen, J.S., Nielsen, D.L., Price, P.A., Balslev, E., Roslind, A., Knoop, A.S., Jensen, Maiken Brit, Johansen, J.S., Nielsen, D.L., Price, P.A., and Balslev, E.

Abstract

YKL-40 is a new biomarker in serum with a prognostic value in several localized and metastatic malignancies. The current knowledge regarding the biological functions of YKL-40 in cancer links YKL-40 to increased aggressiveness of the tumor. Utilizing tissue microarrays, YKL-40 protein expression in tumor tissue was assessed by immunohistochemistry in a cohort of 630 high-risk breast cancer patients with a median estimated potential follow-up time of 10 and 13 years for disease-free (DFS) and overall survival (OS), respectively. YKL-40 protein expression was found in malignant tumor cells and in inflammatory cells. High expression was associated with positive estrogen and progesterone receptor status and high tumor differentiation. Contrary to studies on serum YKL-40 as a prognostic biomarker, a high YKL-40 expression in tumor cells was not significantly associated with DSF and OS in univariate and multivariate analyses Udgivelsesdato: 2008/11

Published
2008

47. Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients> Application of new flow cytometric method.

Author

Svane, I.M., Nikolajsen, K., Hansen, S.W., Kamby, C., Nielsen, D.L., and Johnsen, H.E.

Subjects
DRUG therapy, STEM cell transplantation, BREAST cancer treatment
Abstract

Presents information on a study which analyzed the influence of high-dose chemotherapy and autologous stem cell transplantation on natural and vaccine-induced specific immunity in breast cancer patients. Function of high-dose chemotherapy in the adjuvant treatment for breast cancer; Materials and methodology of the study; Results and discussion.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results